INVEX THERAPEUTICS LTD - Announcements

13.6%

12.5¢

Market Cap $8.266M

Healthcare Biotechnology

Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical... Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical development Company with issued patents and multiple orphan drug designations focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure. Our primary focus is on the orphan disease Idiopathic Intracranial Hypertension (IIH), a large and growing market opportunity with no regulatory cleared treatmentsMore

ASX:PAR

This stock could have something close to a cure for osteoarthritis. Paradigm Biopharmaceuticals (ASX:PAR) is a late-stage drug development company working first and foremost to create a superior treatment for osteoarthritis.

Announcements

Filter Results

All Price Sensitive Only

IXC	First UK Clinical Site Activated in IIH EVOLVE Phase 3 Trial	PRICE SENSITIVE	24/10/22	195.69KB	Share
IXC	First Australian Site Activated in IIH EVOLVE Phase 3	PRICE SENSITIVE	24/10/22	192.5KB	Share
IXC	Notice of Annual General Meeting/Proxy Form		21/10/22	2.11MB	Share
IXC	Second HREC Approval for IIH EVOLVE Phase III Clinical Trial	PRICE SENSITIVE	30/09/22	206.16KB	Share
IXC	Date of AGM and Director Nominations		23/09/22	188.32KB	Share
IXC	Invex to Present at Virtual ASX Small and Mid-Cap Conference		12/09/22	1022.66KB	Share
IXC	Appendix 4G		19/08/22	319.56KB	Share
IXC	Corporate Governance Statement		19/08/22	386.99KB	Share
IXC	4E and Annual Report to shareholders	PRICE SENSITIVE	19/08/22	7.16MB	Share
IXC	Invex receives IND approval	PRICE SENSITIVE	19/08/22	212.82KB	Share
IXC	Trading Halt	PRICE SENSITIVE	18/08/22	212.3KB	Share
IXC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	06/07/22	454.29KB	Share
IXC	HREC and TGA Approval to Commence Phase 3 in Australia	PRICE SENSITIVE	04/07/22	207.47KB	Share
IXC	Appendix 4C and Investor Conference Call Details		01/07/22	190.21KB	Share
IXC	Invex Receives UK Approval to Commence Phase III Trial	PRICE SENSITIVE	29/06/22	201.44KB	Share
IXC	Upcoming Presentations to the 15th EUNOS Meeting		20/06/22	228.83KB	Share
IXC	Invex to Present at Aerospace Medical Association Meeting		20/05/22	232.1KB	Share
IXC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	19/04/22	480.95KB	Share
IXC	March Appendix 4C and Investor Conference Call Details		13/04/22	189.38KB	Share
IXC	Executive Director Agreement		01/04/22	181.9KB	Share
IXC	Invex to Present at Upcoming Tech Biotech Broker Briefing		22/03/22	180.66KB	Share
IXC	Half Yearly Report and Accounts	PRICE SENSITIVE	22/02/22	1.02MB	Share
IXC	Upcoming Presentations at 48th Annual NANOS Meeting		10/02/22	228.5KB	Share
IXC	New Executive Director and Chairman Agreements	PRICE SENSITIVE	31/01/22	200.14KB	Share
IXC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	24/01/22	484.39KB	Share
IXC	Notice of Investor Call and Appendix 4C		21/01/22	186.44KB	Share
IXC	Change of Registry Address		20/12/21	152.9KB	Share
IXC	UK R&D Tax Rebate		20/12/21	192.3KB	Share
IXC	Appointment IIH EVOLVE Phase III Trial Steering Group Chair	PRICE SENSITIVE	17/12/21	190.05KB	Share
IXC	Results of Meeting		25/11/21	246.6KB	Share
IXC	Chairman's Address to Shareholders at AGM		25/11/21	230.85KB	Share
IXC	Withdrawal of AGM Resolutions		23/11/21	185.62KB	Share
IXC	Invex to Present at Bell Potter Healthcare Conference		10/11/21	1.06MB	Share
IXC	Notice of Webinar & Investor Presentation		04/11/21	903.56KB	Share
IXC	Global Phase 3 Trial of Presendin to Launch in Q4 2021	PRICE SENSITIVE	04/11/21	275.06KB	Share
IXC	Notice of Annual General Meeting/Proxy Form		25/10/21	2.37MB	Share
IXC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	20/10/21	494.63KB	Share
IXC	Presentation at EANS 2021 Congress		08/10/21	227.57KB	Share
IXC	Date of AGM and Closing Date for Director Nominations		30/09/21	170.57KB	Share
IXC	Notice of Investor Call and Presentation	PRICE SENSITIVE	27/09/21	891.41KB	Share
IXC	Exclusive Collaboration and Manufacturing Agreement	PRICE SENSITIVE	27/09/21	201.53KB	Share
IXC	Trading Halt	PRICE SENSITIVE	24/09/21	541.45KB	Share
IXC	Corporate Governance Statement		27/08/21	384.65KB	Share
IXC	Appendix 4G		27/08/21	332.52KB	Share
IXC	Appendix 4E and Annual Report	PRICE SENSITIVE	27/08/21	14.93MB	Share
IXC	Invex Granted Key European Patent for Exenatide	PRICE SENSITIVE	16/08/21	185.45KB	Share
IXC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	23/07/21	582.27KB	Share
IXC	Appendix 2A		05/07/21	510.81KB	Share
IXC	Notice of Upcoming Release of Securities from Escrow		23/06/21	176.07KB	Share
IXC	Investor Presentation		21/06/21	847.66KB	Share
IXC	Invex Receives Written Response from FDA on Type C Meeting	PRICE SENSITIVE	15/06/21	189.37KB	Share
IXC	Formulation and Manufacturing Update		07/05/21	185.2KB	Share
IXC	Invex Granted Type C Meeting with FDA	PRICE SENSITIVE	22/04/21	183.16KB	Share
IXC	Appendix 4C - quarterly	PRICE SENSITIVE	13/04/21	506.84KB	Share
IXC	Appendix 3G		09/04/21	287.52KB	Share
IXC	Change of Director's Interest Notice		09/04/21	248.2KB	Share
IXC	Results of Meeting		08/04/21	198.9KB	Share
IXC	Chairman's Address to Shareholders		08/04/21	205.27KB	Share
IXC	Invex Files Pre-IND/Type B Meeting Request with US FDA		31/03/21	186.63KB	Share
IXC	Investor Presentation		18/03/21	934.33KB	Share
IXC	Invex to Present at Upcoming Small Caps Conference		15/03/21	177.46KB	Share
IXC	Postcard to Shareholders		08/03/21	194.29KB	Share
IXC	Notice of General Meeting/Proxy Form		08/03/21	885.39KB	Share
IXC	US Trademark Granted for Presendin		26/02/21	183.47KB	Share
IXC	Initial Director's Interest Notice		16/02/21	244.6KB	Share
IXC	Invex Appoints Dr Megan Baldwin as Non-Executive Director		16/02/21	190.04KB	Share
IXC	Half Yearly Report and Accounts	PRICE SENSITIVE	15/02/21	1.15MB	Share
IXC	Appendix 4C - quarterly	PRICE SENSITIVE	11/01/21	507.99KB	Share
IXC	Invex Successfully Concludes Protocol Assistance with EMA	PRICE SENSITIVE	23/12/20	215KB	Share
IXC	Ceasing to be a substantial holder		02/12/20	1.29MB	Share
IXC	Invex to Present at Bell Potter Healthcare Conference		23/11/20	176.22KB	Share
IXC	Change of Director's Interest Notice		19/11/20	250.22KB	Share
IXC	Appendix 3G		19/11/20	285.11KB	Share
IXC	Results of Meeting		18/11/20	220.07KB	Share
IXC	Chairman's Address to Shareholders and Presentation	PRICE SENSITIVE	18/11/20	444.13KB	Share
IXC	Investor Presentation	PRICE SENSITIVE	05/11/20	1.05MB	Share
IXC	Invex to Present at Upcoming Small Caps Virtual Conference		04/11/20	179.46KB	Share
IXC	Invex Provides Development Update	PRICE SENSITIVE	30/10/20	245.28KB	Share
IXC	Appendix 4C - quarterly	PRICE SENSITIVE	23/10/20	434.95KB	Share
IXC	Amended Appendix 3G		20/10/20	283.96KB	Share
IXC	Amended Appendix 3G		20/10/20	400.59KB	Share
IXC	Appendix 3G		20/10/20	400.75KB	Share
IXC	Notice of Annual General Meeting/Proxy Form		12/10/20	924.88KB	Share
IXC	Final Director's Interest Notice		05/10/20	234.22KB	Share
IXC	Initial Director's Interest Notice		05/10/20	242.83KB	Share
IXC	Director Appointment/Resignation		01/10/20	181.01KB	Share
IXC	AGM Date and Director Nominations		28/09/20	167.97KB	Share
IXC	Appendix 4G		28/08/20	314.97KB	Share
IXC	Corporate Governance Statement		28/08/20	318.01KB	Share
IXC	Appendix 4E and Annual Report	PRICE SENSITIVE	28/08/20	1.22MB	Share
IXC	Quarterly Report and Appendix 4C with appendix	PRICE SENSITIVE	07/08/20	491.53KB	Share
IXC	Conference Call Recording		24/07/20	170.76KB	Share
IXC	Quarterly Report and Appendix 4C	PRICE SENSITIVE	24/07/20	453KB	Share
IXC	Initial FDA and EMA Advice on Presendin Development	PRICE SENSITIVE	23/07/20	223.03KB	Share
IXC	Trading Halt	PRICE SENSITIVE	22/07/20	352.88KB	Share
IXC	Notice of Allowance for Key US Exenatide Patent	PRICE SENSITIVE	21/07/20	177.34KB	Share
IXC	Ceasing to be a substantial holder		03/07/20	121.17KB	Share
IXC	Change of Director's Interest Notice		03/07/20	319.33KB	Share
IXC	Appendix 2A		03/07/20	567.9KB	Share
IXC	Constitution		30/06/20	540.08KB	Share

IXC First UK Clinical Site Activated in IIH EVOLVE Phase 3 Trial
24/10/22	PRICE SENSITIVE	195.69KB	Share
IXC First Australian Site Activated in IIH EVOLVE Phase 3
24/10/22	PRICE SENSITIVE	192.5KB	Share
IXC Notice of Annual General Meeting/Proxy Form
21/10/22		2.11MB	Share
IXC Second HREC Approval for IIH EVOLVE Phase III Clinical Trial
30/09/22	PRICE SENSITIVE	206.16KB	Share
IXC Date of AGM and Director Nominations
23/09/22		188.32KB	Share
IXC Invex to Present at Virtual ASX Small and Mid-Cap Conference
12/09/22		1022.66KB	Share
IXC Appendix 4G
19/08/22		319.56KB	Share
IXC Corporate Governance Statement
19/08/22		386.99KB	Share
IXC 4E and Annual Report to shareholders
19/08/22	PRICE SENSITIVE	7.16MB	Share
IXC Invex receives IND approval
19/08/22	PRICE SENSITIVE	212.82KB	Share
IXC Trading Halt
18/08/22	PRICE SENSITIVE	212.3KB	Share
IXC Quarterly Activities/Appendix 4C Cash Flow Report
06/07/22	PRICE SENSITIVE	454.29KB	Share
IXC HREC and TGA Approval to Commence Phase 3 in Australia
04/07/22	PRICE SENSITIVE	207.47KB	Share
IXC Appendix 4C and Investor Conference Call Details
01/07/22		190.21KB	Share
IXC Invex Receives UK Approval to Commence Phase III Trial
29/06/22	PRICE SENSITIVE	201.44KB	Share
IXC Upcoming Presentations to the 15th EUNOS Meeting
20/06/22		228.83KB	Share
IXC Invex to Present at Aerospace Medical Association Meeting
20/05/22		232.1KB	Share
IXC Quarterly Activities/Appendix 4C Cash Flow Report
19/04/22	PRICE SENSITIVE	480.95KB	Share
IXC March Appendix 4C and Investor Conference Call Details
13/04/22		189.38KB	Share
IXC Executive Director Agreement
01/04/22		181.9KB	Share
IXC Invex to Present at Upcoming Tech Biotech Broker Briefing
22/03/22		180.66KB	Share
IXC Half Yearly Report and Accounts
22/02/22	PRICE SENSITIVE	1.02MB	Share
IXC Upcoming Presentations at 48th Annual NANOS Meeting
10/02/22		228.5KB	Share
IXC New Executive Director and Chairman Agreements
31/01/22	PRICE SENSITIVE	200.14KB	Share
IXC Quarterly Activities/Appendix 4C Cash Flow Report
24/01/22	PRICE SENSITIVE	484.39KB	Share
IXC Notice of Investor Call and Appendix 4C
21/01/22		186.44KB	Share
IXC Change of Registry Address
20/12/21		152.9KB	Share
IXC UK R&D Tax Rebate
20/12/21		192.3KB	Share
IXC Appointment IIH EVOLVE Phase III Trial Steering Group Chair
17/12/21	PRICE SENSITIVE	190.05KB	Share
IXC Results of Meeting
25/11/21		246.6KB	Share
IXC Chairman's Address to Shareholders at AGM
25/11/21		230.85KB	Share
IXC Withdrawal of AGM Resolutions
23/11/21		185.62KB	Share
IXC Invex to Present at Bell Potter Healthcare Conference
10/11/21		1.06MB	Share
IXC Notice of Webinar & Investor Presentation
04/11/21		903.56KB	Share
IXC Global Phase 3 Trial of Presendin to Launch in Q4 2021
04/11/21	PRICE SENSITIVE	275.06KB	Share
IXC Notice of Annual General Meeting/Proxy Form
25/10/21		2.37MB	Share
IXC Quarterly Activities/Appendix 4C Cash Flow Report
20/10/21	PRICE SENSITIVE	494.63KB	Share
IXC Presentation at EANS 2021 Congress
08/10/21		227.57KB	Share
IXC Date of AGM and Closing Date for Director Nominations
30/09/21		170.57KB	Share
IXC Notice of Investor Call and Presentation
27/09/21	PRICE SENSITIVE	891.41KB	Share
IXC Exclusive Collaboration and Manufacturing Agreement
27/09/21	PRICE SENSITIVE	201.53KB	Share
IXC Trading Halt
24/09/21	PRICE SENSITIVE	541.45KB	Share
IXC Corporate Governance Statement
27/08/21		384.65KB	Share
IXC Appendix 4G
27/08/21		332.52KB	Share
IXC Appendix 4E and Annual Report
27/08/21	PRICE SENSITIVE	14.93MB	Share
IXC Invex Granted Key European Patent for Exenatide
16/08/21	PRICE SENSITIVE	185.45KB	Share
IXC Quarterly Activities/Appendix 4C Cash Flow Report
23/07/21	PRICE SENSITIVE	582.27KB	Share
IXC Appendix 2A
05/07/21		510.81KB	Share
IXC Notice of Upcoming Release of Securities from Escrow
23/06/21		176.07KB	Share
IXC Investor Presentation
21/06/21		847.66KB	Share
IXC Invex Receives Written Response from FDA on Type C Meeting
15/06/21	PRICE SENSITIVE	189.37KB	Share
IXC Formulation and Manufacturing Update
07/05/21		185.2KB	Share
IXC Invex Granted Type C Meeting with FDA
22/04/21	PRICE SENSITIVE	183.16KB	Share
IXC Appendix 4C - quarterly
13/04/21	PRICE SENSITIVE	506.84KB	Share
IXC Appendix 3G
09/04/21		287.52KB	Share
IXC Change of Director's Interest Notice
09/04/21		248.2KB	Share
IXC Results of Meeting
08/04/21		198.9KB	Share
IXC Chairman's Address to Shareholders
08/04/21		205.27KB	Share
IXC Invex Files Pre-IND/Type B Meeting Request with US FDA
31/03/21		186.63KB	Share
IXC Investor Presentation
18/03/21		934.33KB	Share
IXC Invex to Present at Upcoming Small Caps Conference
15/03/21		177.46KB	Share
IXC Postcard to Shareholders
08/03/21		194.29KB	Share
IXC Notice of General Meeting/Proxy Form
08/03/21		885.39KB	Share
IXC US Trademark Granted for Presendin
26/02/21		183.47KB	Share
IXC Initial Director's Interest Notice
16/02/21		244.6KB	Share
IXC Invex Appoints Dr Megan Baldwin as Non-Executive Director
16/02/21		190.04KB	Share
IXC Half Yearly Report and Accounts
15/02/21	PRICE SENSITIVE	1.15MB	Share
IXC Appendix 4C - quarterly
11/01/21	PRICE SENSITIVE	507.99KB	Share
IXC Invex Successfully Concludes Protocol Assistance with EMA
23/12/20	PRICE SENSITIVE	215KB	Share
IXC Ceasing to be a substantial holder
02/12/20		1.29MB	Share
IXC Invex to Present at Bell Potter Healthcare Conference
23/11/20		176.22KB	Share
IXC Change of Director's Interest Notice
19/11/20		250.22KB	Share
IXC Appendix 3G
19/11/20		285.11KB	Share
IXC Results of Meeting
18/11/20		220.07KB	Share
IXC Chairman's Address to Shareholders and Presentation
18/11/20	PRICE SENSITIVE	444.13KB	Share
IXC Investor Presentation
05/11/20	PRICE SENSITIVE	1.05MB	Share
IXC Invex to Present at Upcoming Small Caps Virtual Conference
04/11/20		179.46KB	Share
IXC Invex Provides Development Update
30/10/20	PRICE SENSITIVE	245.28KB	Share
IXC Appendix 4C - quarterly
23/10/20	PRICE SENSITIVE	434.95KB	Share
IXC Amended Appendix 3G
20/10/20		283.96KB	Share
IXC Amended Appendix 3G
20/10/20		400.59KB	Share
IXC Appendix 3G
20/10/20		400.75KB	Share
IXC Notice of Annual General Meeting/Proxy Form
12/10/20		924.88KB	Share
IXC Final Director's Interest Notice
05/10/20		234.22KB	Share
IXC Initial Director's Interest Notice
05/10/20		242.83KB	Share
IXC Director Appointment/Resignation
01/10/20		181.01KB	Share
IXC AGM Date and Director Nominations
28/09/20		167.97KB	Share
IXC Appendix 4G
28/08/20		314.97KB	Share
IXC Corporate Governance Statement
28/08/20		318.01KB	Share
IXC Appendix 4E and Annual Report
28/08/20	PRICE SENSITIVE	1.22MB	Share
IXC Quarterly Report and Appendix 4C with appendix
07/08/20	PRICE SENSITIVE	491.53KB	Share
IXC Conference Call Recording
24/07/20		170.76KB	Share
IXC Quarterly Report and Appendix 4C
24/07/20	PRICE SENSITIVE	453KB	Share
IXC Initial FDA and EMA Advice on Presendin Development
23/07/20	PRICE SENSITIVE	223.03KB	Share
IXC Trading Halt
22/07/20	PRICE SENSITIVE	352.88KB	Share
IXC Notice of Allowance for Key US Exenatide Patent
21/07/20	PRICE SENSITIVE	177.34KB	Share
IXC Ceasing to be a substantial holder
03/07/20		121.17KB	Share
IXC Change of Director's Interest Notice
03/07/20		319.33KB	Share
IXC Appendix 2A
03/07/20		567.9KB	Share
IXC Constitution
30/06/20		540.08KB	Share

REFRESH

First 2

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 12.5¢		Change 0.015(13.6%)		Mkt cap ! $8.266M

Open	High	Low	Value	Volume
11.0¢	12.5¢	11.0¢	$1.051K	8.893K

Buyers (Bids)

No.	Vol.	Price($)
1	5727	10.5¢

Sellers (Offers)

Price($)	Vol.	No.
12.5¢	40146	2

View Market Depth

No.	Vol.	Price($)
1	5727	0.105
1	12000	0.100
1	50000	0.095
1	100000	0.091
1	50000	0.087

Price($)	Vol.	No.
0.125	40146	2
0.145	2000	1
0.150	713	1
0.000	0	0
0.000	0	0

Last trade - 10.11am 17/09/2025 (20 minute delay)

IXC (ASX) Chart

INVEX THERAPEUTICS LTD - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories